A Phase 1b/2, Open-label, Multicenter, Dose-escalation a

Project: Research project

Project Details

Description

A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma
StatusFinished
Effective start/end date9/1/1611/30/18

Funding

  • DYNAVAX TECHNOLOGIES CORPORATION

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.